You are previewing Pharmacoinformatics and Drug Discovery Technologies.
O'Reilly logo
Pharmacoinformatics and Drug Discovery Technologies

Book Description

Within the context of integrated health management domains, pharmacoinformatics aims at maximizing the benefits from the use of information systems and technologies for the provision of decision support tools necessary for improved drug management, use, and administration practices.Pharmacoinformatics and Drug Discovery Technologies: Theories and Applications offers the latest the field has to offer to practitioners and academics alike, presented through theoretical frameworks, case studies, and future directions. This vital resource gathers an integrated pattern of high quality publications from around the world providing current, current-edge, and provocative scientific work in the three domains of pharmacoinformatics: decision making domains, knowledge utilization and representation environment, and the technological and infrastructural context.

Table of Contents

  1. Cover
  2. Title Page
  3. Copyright Page
  4. Editorial Advisory Board and List of Reviewers
    1. Editorial Advisory Board
    2. List of Reviewers
  5. Preface
  6. Section 1: Contextual Analysis of the Domain of Pharmacoinformatics
    1. Chapter 1: Pharmacoinformatics
      1. ABSTRACT
      2. INTRODUCTION
      3. PHARMACY MANAGEMENT AND PHARMACEUTICAL CARE
      4. THE CONTEXT OF PHARMACOINFORMATICS
      5. PHARMACOINFORMATICS APPLICATIONS AND TECHNOLOGIES
      6. CRITICAL SUCCESS FACTORS
      7. CONCLUSION
    2. Chapter 2: Informatics for Medicines Management Systems in Resource-Limited Settings
      1. ABSTRACT
      2. INTRODUCTION
      3. WHAT ARE THE NEEDS FOR PHARMACEUTICAL SYSTEMS INFORMATICS IN DEVELOPING COUNTRIES?
      4. CHALLENGES TO MEDICINES MANAGEMENT SYSTEMS INFORMATICS IN DEVELOPING COUNTRIES
      5. KEY CONSIDERATIONS FOR PHARMACEUTICAL SYSTEMS INFORMATICS IN DEVELOPING COUNTRIES
      6. CASE EXAMPLES OF APPLICATIONS
      7. A FRAMEWORK FOR MEETING THE CHALLENGES THROUGH MEDICINES MANAGEMENT INFORMATICS SYSTEMS
    3. Chapter 3: The Humane Dimensions of Effective Communication
      1. ABSTRACT
      2. INTRODUCTION
      3. BACKGROUND
      4. ISSUES
      5. LOOKING OVER OUR SHOULDER
      6. COMMITMENT AND EXPERTISE
      7. SOCIAL MEDIA
      8. RISK AND UNCERTAINTY
      9. ONE-TO-ONE
      10. THE EXAMPLE OF PUBLIC CAMPAIGNS IN HEALTH AND SAFETY
      11. THE MULTIPLE CHALLENGES OF COMMUNICATING BENEFIT AND RISK
      12. MAXIMISING PATIENT SAFETY
      13. THE RISKS OF MANAGEMENT AND FINANCIAL EFFICIENCY TARGETS
      14. ERRORS
      15. AVOIDING DISASTERS: COMMUNICATIONS PLAY A BIG PART
      16. SO WHAT ABOUT HEALTHCARE DISASTERS?
      17. IT ALL COMES DOWN TO THE QUALITY OF COMMUNICATIONS
      18. THE HAZARDS OF VACCINATION
      19. WHAT IS TO BE DONE?
      20. FUTURE RESEARCH DIRECTIONS
      21. CONCLUSION: HEAD AND HEART
    4. Chapter 4: The Role of Pharmacoinformatics in Enhancing the Pharmacoeconomics Context of Decision Making
      1. ABSTRACT
      2. INTRODUCTION
      3. TRANSFERABILITY AND WEB-BASED ACCESS TO MODELS: SOME EXAMPLES
      4. DECISION SUPPORT
      5. WEB TECHNOLOGY
      6. DISCUSSION
      7. CONCLUSION
  7. Section 2: Pharmacoinformatics-Oriented Business Models
    1. Chapter 5: Key Issues and Challenges for Managing and Evaluating B2B E-Commerce Projects within the Australian Pharmaceutical Supply Chain
      1. ABSTRACT
      2. INTRODUCTION
      3. B2B E-COMMERCE IN PHARMACEUTICAL SUPPLY CHAIN
      4. EVALUATION OF B2B E-COMMERCE
      5. BENEFITS REALIZATION IN B2B E-COMMERCE
      6. B2B E-COMMERCE MANAGEMENT
      7. CHALLENGES FOR B2B E-COMMERCE MANAGEMENT AND EVALUATION
      8. RESEARCH METHODOLOGY
      9. RESEARCH FINDINGS
      10. KEY MANAGEMENT ISSUES AND CHALLENGES
      11. DISCUSSIONS AND CONCLUSION
      12. FUTURE TRENDS
    2. Chapter 6: Collaborations for Innovation in the Bio-Pharmaceutical Industry
      1. ABSTRACT
      2. INTRODUCTION
      3. RESEARCH BACKGROUND
      4. RESEARCH METHODOLOGY
      5. RESEARCH FINDINGS
      6. CONCLUSION AND FUTURE TRENDS
    3. Chapter 7: Cost-Effectiveness Analysis and the Value for Money of Health Technologies
      1. ABSTRACT
      2. INTRODUCTION
      3. BACKGROUND
      4. METHODOLOGICAL BASIS OF THE ICER
      5. FUTURE RESEARCH DIRECTIONS
      6. CONCLUSION
    4. Chapter 8: A Preliminary Study of the Practices and Processes of B2B E-Commerce Evaluation and Benefits Realization in Taiwanese Hospitals
      1. ABSTRACT
      2. INTRODUCTION
      3. B2B E-COMMERCE
      4. IT/B2B INVESTMENT EVALUATION AND BENEFITS REALIZATION
      5. ORGANIZATIONAL IT MATURITY
      6. IT EVALUATION RESOURCES ALLOCATION
      7. USER SATISFACTION
      8. PATIENT SATISFACTION
      9. SIGNIFICANCE OF RESEARCH
      10. RESEARCH METHODOLOGY
      11. RESEARCH FINDINGS
      12. DISCUSSION AND CONCLUSION
      13. FUTURE TRENDS
  8. Section 3: Methodologies, Technologies, and Applications of Pharmacoinformatics
    1. Chapter 9: The Evolving Role of Pharmacoinformatics in Targeting Drug-Related Problems in Clinical Oncology Practice
      1. ABSTRACT
      2. INTRODUCTION
      3. BACKGROUND
      4. EVOLVING ROLES OF PHARMACOINFORMATICS IN THE AREA OF ONCOLOGY
      5. THE PARADIGM SHIFT IN DRUG-RELATED PROBLEMS EXPERIENCED BY PATIENTS WITH CANCER IN THE CYBERMEDICINE ERA
      6. CLINICALLY-RELEVANT DRUG INTERACTIONS IN ONCOLOGY: A HEALTHCARE PRACTITIONER’S PERSPECTIVE
      7. PHARMACOINFORMATICS CHANNELS FOR ONCOLOGY HEALTH PRACTITIONERS AND PATIENTS WITH CANCER
      8. ASSESSING THE QUALITY OF PHARMACOINFORMATICS CHANNELS THAT PROVIDE ONCOLOGY DRUG INTERACTION INFORMATION
      9. CONCLUSION
    2. Chapter 10: Clinical Pharmacists’ Intervention Documentation in Germany with DokuPIK
      1. ABSTRACT
      2. CLINICAL PHARMACISTS IN GERMANY
      3. SYSTEMS FOR THE DOCUMENTATION OF PHARMACISTS INTERVENTIONS IN GERMANY
      4. FURTHER DIRECTIONS
    3. Chapter 11: A Multi Agent Pharmacoinformatics Reference Model for the Improvement of Hospital Management
      1. ABSTRACT
      2. INTRODUCTION
      3. SIGNIFICANCE OF THE STUDY
      4. CONCLUSION
    4. Chapter 12: The Health Care Factory
      1. ABSTRACT
      2. INTRODUCTION
      3. MODEL OF THE HEALTH CARE FACTORY
      4. HEALTH CARE FACTORY: THE UNDERLYING MIDDLEWARE
      5. RELATED WORK
      6. CONCLUSION
    5. Chapter 13: New Technologies in Personalized Decision Support to Enhance Patient Choice
      1. ABSTRACT
      2. INTRODUCTION
      3. EVIDENCE THAT PERSONALIZATION ENHANCES EFFECTIVENESS
      4. ISSUES AND CONTROVERSIES
      5. COMPOSITE END POINTS
      6. CONCLUSION
    6. Chapter 14: Social Network Sites and Their Role in the Sharing of Health Information
      1. ABSTRACT
      2. BACKGROUND
      3. WHY PEOPLE USE SOCIAL NETWORK SITES
      4. SNS AND HEALTH INFORMATION
      5. PRIVACY ISSUES
      6. FUTURE TRENDS
      7. CONCLUSION
    7. Chapter 15: Enforcing Data Integrity in Pharmacy
      1. ABSTRACT
      2. INTRODUCTION
      3. BACKGROUND
      4. ENFORCING DATA INTEGRITY
      5. TOP-DOWN APPROACH
      6. FIRST NORMAL FORM (1NF)
      7. SECOND NORMAL FORM (2NF)
      8. THIRD NORMAL FORM
      9. BOYCE-CODD NORMAL FORM (BCNF)
      10. DATA ENTRY
      11. SECURITY
      12. FUTURE
      13. CONCLUSION
    8. Chapter 16: Statistical Methods Applied in Drug Safety
      1. ABSTRACT
      2. INTRODUCTION
      3. BACKGROUND
      4. STATISTICAL METHODS USED FOR DRUG SAFETY
      5. BEST PRACTICES
      6. FUTURE TRENDS
      7. CONCLUSION
  9. Section 4: Multidisciplinary Context of Pharmacoinformatics
    1. Chapter 17: An Optimization to Protein Coding Regions Identification in Eukaryotes
      1. ABSTRACT
      2. INTRODUCTION
      3. RELATED WORK
      4. PROPOSED SOLUTION
      5. RESULTS AND DISCUSSION
      6. CONCLUSION
    2. Chapter 18: Pharmaco-EcoMicrobiology and Its Potential Role in Medical and Environmental Sciences
      1. ABSTRACT
      2. INTRODUCTION
      3. INTERRELATION AMONG PHARMACOLOGY, MICROBIOLOGY, AND ECOLOGY, AND THEIR IMPLICATIONS IN MEDICAL SCIENCE
      4. APPLICATION OF PEcM IN APPLIED MEDICINE
      5. RELATION OF PHARMACO-ECOMICROBIOLOGY (PEcM) WITH PHARMACOINFORMATICS
      6. ROLE OF DRUG ADULTERATION AND UNQUALIFIED MEDICAL PRACTITIONERS IN RURAL AREAS OF DEVELOPING NATIONS AND THEIR DETRIMENTAL EFFECTS ON HUMAN HEALTH AND ECOSYSTEM
      7. DETRIMENTAL EFFECT OF CHEMICALS ON THE ENVIRONMENT AND LIVING ORGANISMS
      8. DISASTER MANAGEMENT AND BIOLOGICAL WARFARE
      9. CONCLUSION
    3. Chapter 19: In Silico Pharmaco-Gene-Informatic Identification of Insulin-Like Proteins in Plants
      1. ABSTRACT
      2. INTRODUCTION
      3. BACKGROUND
      4. RESULTS OF IN SILICO INVESTIGATIONS
      5. COMMENT
      6. CONCLUSION
  10. Section 5: Pharmacovigilance Issues and Concepts
    1. Chapter 20: Pharmacovigilance
      1. ABSTRACT
      2. INTRODUCTION
      3. DEFINITION AND TERMINOLOGIES
      4. EPIDEMIOLOGY AND IMPLICATIONS OF ADRS
      5. CLASSIFICATION OF ADRS
      6. PREDISPOSING FACTORS FOR ADRS
      7. IMPORTANCE OF PHARMACOVIGILANCE
      8. SURVEILLANCE METHODS IN PHARMACOVIGILANCE
      9. EVALUATION OF INDIVIDUAL ADRS
      10. ROLES OF VARIOUS PROFESSIONALS IN PHARMACOVIGILANCE
      11. INTERNATIONAL REGULATORY AGENCIES ON PHARMACOVIGILANCE AND INFLUENCE OF PHARMACOINFORMATICS
      12. PHARMACOINFORMATICS: VARIOUS ARENAS
      13. TERMINOLOGIES
      14. FUTURE OF PHARMACOINFORMATICS IN IMPROVING PHARMACOVIGILANCE
      15. CONCLUSION
    2. Chapter 21: The Role of Pharmacovigilance Center in Sudan in Reporting Adverse Drug Reactions
      1. ABSTRACT
      2. INTRODUCTION
      3. TYPES OF ADVERSE DRUG REACTIONS
      4. MECHANISMS OF ADVERSE DRUG REACTIONS
      5. DETECTION AND MONITORING OF ADRS
      6. METHODS OF PHARMACOVIGILANCE
      7. HYPOTHESIS-GENERATING METHODS
      8. HYPOTHESIS-TESTING METHODS
      9. ROLE OF INTERNATIONAL ORGANIZATIONS
      10. SUDAN PHARMACOVIGILANCE CENTER
      11. CHALLENGES AHEAD
  11. Compilation of References
  12. About the Contributors
  13. Index